Cassava Sciences (SAVA)

• Market cap: $135M
• 1 day: -1.41%
• 5 days: 1.82%
• 1 month: 12.00%
• 3 months: 19.66%
• 6 months: -90.53%
• Year to date: 1.82%
• 1 year: -85.79%
• 5 years: -9.97%
• 10 years: -70.21%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Employees: 30

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

26% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 35

6.87% more ownership

Funds ownership: 29.27% [Q3] → 36.13% (+6.87%) [Q4]

14% less funds holding

Funds holding: 160 [Q3] → 137 (-23) [Q4]

38% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 52

63% less call options, than puts

Call options by funds: $10.1M | Put options by funds: $27.2M

87% less capital invested

Capital invested by funds: $412M [Q3] → $51.8M (-$360M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]